Prevention of preeclampsia: Is it possible?

Clinical Obstetrics and Gynecology

Volumn 42, Issue 3, 1999, Pages 436-454

  Norwitz, Errol R ^a   Robinson, Julian N ^a   Repke, John T ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM; DIPYRIDAMOLE; DIURETIC AGENT; HEPARIN; HYDROCHLOROTHIAZIDE; MAGNESIUM; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; SODIUM; THIAZIDE DIURETIC AGENT; ZINC;

BED REST; DIET SUPPLEMENTATION; DRUG CONTRAINDICATION; FEMALE; HIGH RISK PATIENT; HUMAN; PREECLAMPSIA; REVIEW; SCREENING TEST; SODIUM RESTRICTION;

ASPIRIN; CYCLOOXYGENASE INHIBITORS; DIETARY SUPPLEMENTS; FEMALE; HUMANS; MASS SCREENING; PRE-ECLAMPSIA; PREGNANCY; RISK FACTORS;

EID: 0033395675     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-199909000-00003     Document Type: Review

References (100)

1. Rochat RW, Koonin LM, Atrash JF, the Maternal Mortality Collaborative. Maternal mortality in the Unites States: Report from the Maternal Morality Collaborative. Obstet Gynecol. 1988;72:91-97.
2. Committee on Obstetrics. Hypertension in pregnancy. Washington, DC: American College of Obstetricians and Gynecologists, 1996. American College of Obstetricians and Gynecologists Technical Bulletin Number 219.
3. Odendaal HJ, Pattinson RC, Bam R, Grove D, Kotze TJvW. Aggressive or expectant management for patients with severe preeclampsia between 28-34 weeks' gestation: A randomized controlled trial. Obstet Gynecol. 1990;76:1070-1074.
4. Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: A randomized controlled trial. Am J Obstet Gynecol. 1994;171:818-822.
5. Cnattingius S, Mills JL, Yuen J, Eriksson O, Ros HS. The paradoxical effect of smoking in preeclamptic pregnancies: Smoking reduces the incidence but increases the rates of perinatal mortality, abruptio placentae, and intrauterine growth restriction. Am J Obstet Gynecol. 1997;177:156-161.
6. Robillard P-Y, Hulsey TC, Perianin J, Janky E, Miri EH, Papiernik E. Association of pregnancy-induced hypertension with duration of sexual cohabitation before conception. Lancet. 1994;344:973-975.
7. Moutquin JM, Rainville C, Giroux L, et al. A prospective study of blood pressure in pregnancy: Prediction of preeclampsia. Am J Obstet Gynecol. 1985;151:191-196.
8. Page EW, Christianson R. The impact of mean arterial pressure in the second trimester upon the outcome of pregnancy. Am J Obstet Gynecol. 1976;125:740-746.
9. Villar MA, Sibai BM. Clinical significance of elevated mean arterial blood pressure in second trimester and threshold increase in systolic or diastolic blood pressure during the third trimester. Am J Obstet Gynecol. 1989;160:419-423.
10. Hermida RC, Ayala DE, Mojon A, Iglesias M. High sensitivity test for the early diagnosis of gestational hypertension and preeclampsia. J Perinat Med. 1997;25:153-167.
11. Tomoda S, Kitanaka T, Ogita S, Hidaka A. Prediction of pregnancy-induced hypertension by isometric exercise. Asia Oceania J Obstet Gynaecol. 1994;20:249-255.
12. Marya RK, Rathee S, Mittal R. Evaluation of three clinical tests for predicting pregnancy-induced hypertension. Am J Obstet Gynecol. 1988;158:683-684.
13. Gant NF, Chand S, Worley RJ, Whalley PJ, Crosby UD, MacDonald PC. A clinical test useful for predicting the development of acute hypertension in pregnancy. Am J Obstet Gynecol. 1974;120:1-6.
14. Dekker GA, Makovitz JW, Wallenburg HCS. Comparison of prediction of pregnancy-induced hypertensive disease by angiotensin II sensitivity and supine pressor test. Br J Obstet Gynaecol. 1990;97: 817-821.
15. Oney T, Kaulhausen H. The value of the angiotensin sensitivity test in the early diagnosis of hypertensive disorders in pregnancy. Am J Obstet Gynecol. 1982;142: 17-20.
16. Dekker GA, Sibai BM. Early detection of preeclampsia. Am J Obstet Gynecol. 1991;165:160-172.
17. Sagen N, Haram K, Nilsen ST. Serum urate as a predictor of fetal outcome in severe preeclampsia. Acta Obstet Gynecol Scand. 1984;63:71-75.
18. Weiner CP, Kwaan HC, Xu C, Paul M, Burmeister L, Hauck W. Antithrombin III activity in women with hypertension during pregnancy. Obstet Gynecol. 1985;65: 301-306.
19. Dreyfus M, Baldauf JJ, Ritter J, Van Cauwenberg JR, Hardy A, Foidart JM. The prediction of preeclampsia: Reassessment of clinical value of increased plasma levels of fibronectin. Eur J Obstet Gynecol Reprod Biol. 1998;78:25-28.
20. Rodriguez MH, Masaki DI, Mestman J, Kumar D, Rude R. Calcium/creatinine ratio and microalbuminuria in the prediction of preeclampsia. Am J Obstet Gynecol. 1988;159:1452-1455.
21. Fitzgerald DJ, Entman SS, Mulloy K, Fitzgerald GA. Decreased prostacyclin biosynthesis preceding the clinical manifestations of pregnancy-induced hypertension. Circulation. 1987;75:956-963.
22. Jacob M, Wilfred G, Kanagasabapathy AS, Balasubramaniam N. Urinary N-acetyl-β-D-glucosaminidase in the prediction of preeclampsia and pregnancy-induced hypertension. Aust NZJ Obstet Gynaecol. 1993;33:395-397.
23. Kyle PM, Campbell S, Buckley D, et al. A comparison of the inactive urinary kallikrein:creatinine ratio and the angiotensin sensitivity test for the prediction of preeclampsia. Br J Obstet Gynaecol. 1996; 103:981-987.
24. Millar JG, Campbell SK, Albano JD, Higgins BR, Clark AD. Early prediction of preeclampsia by measurement of kallikrein and creatinine on a random urine sample. Br J Obstet Gynaecol. 1996;103: 421-426.
25. Harrington K, Cooper D, Lees C, Hecher K, Campbell S. Doppler ultrasound of the uterine arteries: The importance of bilateral notching in the prediction of preeclampsia, placental abruption, or delivery of a small for gestational age baby. Ultrasound Obstet Gynecol. 1996;7:182-188.
26. Irion O, Masse J, Forest JC, Moutquin JM. Prediction of preeclampsia, low birthweight for gestation, and prematurity by uterine artery blood flow velocity waveforms analysis in low-risk nulliparous women. Br J Obstet Gynaecol. 1998;105: 422-429.
27. Campbell S, Pearce JMF, Hackett G, Cohen-Overbeek T, Hernandez C. Qualitative assessment of uteroplacental blood flow: Early screening test for high-risk pregnancies. Obstet Gynecol. 1986;68: 649-653.
28. Arduini D, Rizzo G, Romanini C, Mancuso S. Uteroplacental blood flow velocity waveforms as predictors of pregnancy-induced hypertension. Eur J Obstet Gynecol Reprod Biol. 1987;26:335-341.
29. MacGillivray I, Campbell D, Pirani BB. Changes preceding the development of preeclamptic toxemia. Isr J Med Sci. 1976;12:504-507.
30. Steegers EA, Eskes TK, Jongsma HW, Hein PR. Dietary sodium restriction during pregnancy: A historical review. Eur J Obstet Gynecol Reprod Biol. 1991;40:83-90.
31. Gratacos E, Casals E, Sanllehy C, Cararach V, Alonso PL, Fortuny A. Variation in lipid levels during pregnancy in women with different types of hypertension. Acta Obstet Gynecol Scand. 1996;75:896-901.
32. Hubel CA, McLaughlin MK, Evans RW, Hauth BA, Sims CJ, Roberts JM. Fasting serum triglycerides, free fatty acids, and malondialdehyde are increased in preeclampsia, are positively correlated, and decrease within 48 hours postpartum. Am J Obstet Gynecol. 1996;174:975-982.
33. Jain SK, Wise R. Relationship between elevated lipid peroxides, vitamin E deficiency, and hypertension in preeclampsia. Mol Cell Biochem. 1995;151:33-38.
34. Mikhail MS, Anyaegbunam A, Garfinkel D, Palan PR, Basu J, Romney SL. Preeclampsia and antioxidant nutrients: Decreased plasma levels of reduced ascorbic acid, alpha-tocopherol, and beta-carotene in women with preeclampsia. Am J Obstet Gynecol. 1994;171:150-157.
35. Schiff E, Friedman SA, Stampfer M, Kao L, Barrett PH, Sibai BM. Dietary consumption and plasma concentrations of vitamin E in pregnancies complicated by preeclampsia. Am J Obstet Gynecol. 1996;175:1024-1028.
36. Olsen SF, Secher NJ. A possible preventive effect of low-dose fish oil on early delivery and preeclampsia: Indications for a 50-year-old controlled trial. Br J Nutr. 1990;64:599-609.
37. Williams MA, Zingheim RW, King IB, Zebelman AM. Omega-3 fatty acids in maternal erythrocytes and risk of preeclampsia. Epidemiology. 1995;6:232-237.
38. Adair CD, Sanchez-Ramos L, Briones DL, Ogburn P Jr. The effect of high dietary n-3 fatty acid supplementation on angiotensin II pressor response in human pregnancy. Am J Obstet Gynecol. 1996; 175:688-691.
39. Laivuori H, Hovatta O, Viinikka L, Ylikorkala O. Dietary supplementation with primrose oil or fish oil does not change urinary excretion of prostacyclin and thromboxane metabolites in preeclamptic women. Prostaglandins Leukot Essent Fatty Acids. 1993;49:691-694.
40. Salvig JD, Olsen SF, Secher NJ. Effects of fish oil supplementation in late pregnancy on blood pressure: A randomized controlled trial. Br J Obstet Gynaecol. 1996; 103:529-533.
41. Lazebnik N, Kuhnert BR, Kuhnert PM. Zinc, cadmium, and hypertension in parturient women. Am J Obstet Gynecol. 1989;161:437-440.
42. Mohamed K, James DK, Golding J, McCabe R. Zinc supplementation during pregnancy: A double blind randomized clinical trial. BMJ 1989;299:826-830.
43. Jonsson B, Hauge B, Larsen NF, Hald F. Zinc supplementation during pregnancy: A double blind randomized clinical trial. Acta Obstet Gynaecol Scand. 1996;75: 725-729.
44. Sibai BM, Villar MA, Bray E. Magnesium supplementation during pregnancy: A double blind randomized controlled clinical trial. Am J Obstet Gynecol. 1989;161: 115-19.
45. Crowther C, Chalmers I. Bed rest and hospitalization during pregnancy. In: Chalmers I, Enkin M, Keirse MJN, eds. Effective Care in Pregnancy and Childbirth. Oxford: Oxford University Press, 1989:624-632.
46. Collins R, Yusuf S, Peto R. Overview of randomized trials of diuretics in pregnancy. BMJ 1985;290:17-23.
47. Walker JJ. Hypertensive drugs in pregnancy. Antihypertension therapy in pregnancy, preeclampsia, and eclampsia. Clin Perinatol. 1991;18:845-873.
48. Goodlin RC, Haesslein HO, Fleming J. Aspirin for the treatment of recurrent toxemia [letter]. Lancet. 1978;2:51.
49. Beaufils M, Uzan S, Donsimoni R, Colau JC. Prevention of preeclampsia by early antiplatelet therapy. Lancet. 1985;1:840-842.
50. Wallenburg HCS, Dekker GA, Makovitz JW, Rotmans P. Low-dose aspirin prevents pregnancy-induced hypertension and preeclampsia in angiotensin-sensitive primigravidae. Lancet. 1986;1:1-3.
51. 2 to prostacyclin in relatively high risk pregnancies. N Engl J Med. 1989;321:351-356.
52. Benigni A, Gregorini G, Frusca T, et al. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med. 1989;321:357-362.
53. McParland P, Pearce JM, Chamberlain GVP. Doppler ultrasound and aspirin in recognition and prevention of pregnancy-induced hypertension. Lancet. 1990;335: 1552-1555.
54. Uzan S, Beaufils M, Breart G, Bazin B, Capitant C, Paris J. Prevention of fetal growth retardation with low-dose aspirin: Findings of the EPRENA trial. Lancet. 1991;337:1427-1431.
55. Hauth JC, Goldenberg RL, Parker CR Jr, et al. Low-dose aspirin therapy to prevent preeclampsia. Am J Obstet Gynecol. 1993;168:1083-1093.
56. Viinikka L, Hartikainen-Sorri AL, Lumme R, Hiilesmaa V, Ylikorkala O. Low-dose aspirin in hypertensive pregnant women: Effect on pregnancy outcome and prostacyclin-thromboxane balance in mother and newborn. Br J Obstet Gynaecol. 1993;100:809-815.
57. Imperiale TF, Petrulis AS. A meta-analysis of low-dose aspirin for the prevention of pregnancy-induced hypertensive disease. JAMA.1991;266:261-264.
58. Dekker GA, Sibai BM. Low-dose aspirin: The prevention of preeclampsia and fetal growth retardation: Rationale, mechanisms, and clinical trials. Am J Obstet Gynecol. 1993;168:214-227.
59. Italian Study of Aspirin in Pregnancy. Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Lancet. 1993;341:396-400.
60. Sibai BM, Caritis SN, Thom E, et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. N Engl J Med. 1993;329:1213-1218.
61. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: A randomized trial of low-dose aspirin for the prevention and treatment of preeclampsia among 9,364 pregnant women. Lancet. 1994;343:619-629.
62. Wang Z, Li W. A prospective randomized placebo-controlled trial of low-dose aspirin for prevention of intrauterine growth retardation. Chin Med J (Engl). 1996;109: 238-242.
63. ECPPA (Estudo Colaborativo para Prevencao de Preeclampsia com Aspirina) Collaborative Group. ECPPA: Randomized trial of low-dose aspirin for the prevention of maternal and fetal complications in high-risk pregnant women. Br J Obstet Gynaecol. 1996;103:39-47.
64. Golding J and The Jamaica Low-dose Aspirin Study Group. A randomized trial of low-dose aspirin for primiparae in pregnancy. Br J Obstet Gynaecol. 1998;105: 293-299.
65. Rotchell YE, Cruickshank JK, Phillips-Gay M, et al. Barbados Low-dose Aspirin Study in Pregnancy (BLASP): A randomized trial for the prevention of preeclampsia and its complications. Br J Obstet Gynaecol. 1998;105:286-292.
66. Caritis S, Sibai BM, Hauth J, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med. 1998; 338:701-705.
67. Harrington K, Carpenter RG, Goldfrad C, Campbell S. Transvaginal Doppler ultrasound of the uteroplacental circulation in the early prediction of preeclampsia and intrauterine growth retardation. Br J Obstet Gynaecol. 1997;104:674-681.
68. Hermida C, Ayala DE, Iglesias M, et al. Time-dependent effects of low-dose aspirin administration on blood pressure in pregnant women. Hypertension. 1997;30: 589-595.
69. Zierler S. Maternal drugs and congenital heart disease. Obstet Gynecol. 1985;65: 155-165.
70. Belizan JM, Villar J, Repke JT. The relationship between calcium intake and pregnancy-induced hypertension: Up-to-date evidence. Am J Obstet Gynecol. 1988; 158:898-902.
71. Bucher H, Guyatt GH, Cook RJ, et al. Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: A meta-analysis of randomized controlled trials. JAMA. 1996;275:1113-1117.
72. Seely EW, Wood RJ, Brown EM, Graves SW. Lower serum ionized calcium and abnormal calciotropic hormone levels in preeclampsia. J Clin Endocrinol Metab. 1992;74:1436-1440.
73. Lopez-Jaramillo P, Delgado F, Jacome P, et al. Calcium supplementation and the risk of preeclampsia in Ecuadorian pregnant teenagers. Obstet Gynecol. 1997;90: 162-167.
74. Conde-Agudelo A, Lede R, Belizan J. Evaluation of methods used in the prediction of hypertensive disorders of pregnancy. Obstet Gynecol Surv. 1994;49: 210-222.
75. Hatton DC, McCarron DA. Dietary calcium and blood pressure in experimental models of hypertension. Hypertension. 1994;23: 513-530.
76. Kawasaki N, Matsui K, Masaharu I, Nakamura T, Yoshimura T, Hidetaka U. Effect of calcium supplementation on the vascular sensitivity to angiotensin II in pregnant women. Am J Obstet Gynecol. 1985;153:576-582.
77. Marya RK, Rathee S, Manrow M. Effect of calcium and vitamin D supplementation on toxemia of pregnancy. Gynecol Obstet Invest. 1987;24:38-42.
78. Villar J, Repke JT, Belizan JM, Pareja G. Calcium supplementation reduces blood pressure during pregnancy: Results of a randomized controlled clinical trial. Obstet Gynecol. 1987;70:317-322.
79. Lopez-Jaramillo P, Narvaez M, Weigel RM, Yepez R. Calcium supplementation reduces the risk of pregnancy-induced hypertension in an Andes population. Br J Obstet Gynaecol. 1989;96:648-655.
80. Lopez-Jaramillo P, Narvaez M, Felix C, Lopez A. Dietary calcium supplementation and prevention of pregnancy hypertension. Lancet. 1990;335:293.
81. Montanaro D, Boscutti G, Mioni G, et al. Calcium supplementation decreases the incidence of pregnancy-induced hypertension (PIH) and preeclampsia. Presented at the Seventh World Congress of Hypertension in Pregnancy, 1990; Perugia, Italy. Abstract 91.
82. Villar J, Repke JT. Calcium supplementation during pregnancy may reduce preterm delivery in high-risk populations. Am J Obstet Gynecol. 1990;163:124-131.
83. Belizan JM, Villar J, Gonzalez L, Campodonico L, Bergel E. Calcium supplementation to prevent hypertensive disorders of pregnancy. N Engl J Med. 1991;325: 1399-1405.
84. Cong KJ, Chi SL, Liu CR. Calcium and pregnancy-induced hypertension. Am J Obstet Gynecol. 1993;28:1-10.
85. Sanchez-Ramos L, Briones DK, Kaunitz AM, et al. Prevention of pregnancy-induced hypertension by calcium supplementation in angiotensin II-sensitive patients. Obstet Gynecol. 1994;84:349-353.
86. Carroli G, Duley L, Belzian JM, Villar J. Calcium supplementation during pregnancy: A systematic review of randomized controlled trials. Br J Obstet Gynaecol. 1994;101:753-758.
87. Purwar M, Kulkarni H, Motghare V, et al. Calcium supplementation and prevention of pregnancy-induced hypertension. J Obstet Gynaecol Res. 1996;22:425-430.
88. Levine RJ, Esterlitz JR, Raymond EG, et al. Trial of Calcium for Preeclampsia Prevention (CPEP): Rationale, design, and methods. Control Clin Trials. 1996;17: 442-469.
89. Levine RJ, DerSimonian R. Effects of calcium supplementation on pregnancy-induced hypertension. JAMA. 1996;276: 1387.
90. Levine RJ, Hauth JC, Curt LB, et al. Trial of calcium to prevent preeclampsia. N Engl J Med. 1997;337:69-76.
91. Herrera JA, Arevalo-Herrera M, Herrera S. Prevention of preeclampsia by linoleic acid and calcium supplementation: A randomized controlled trial. Obstet Gynecol. 1998;91:585-590.
92. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997;336:1117-1124.
93. Richardson BE, Baird DD. A study of milk and calcium supplement intake and subsequent preeclampsia in a cohort of pregnant women. Am J Epidemiol. 1995; 141:667-673.
94. North RA, Ferrier C, Gamble G, et al. Prevention of preeclampsia with heparin and antiplatelet drugs in women with renal disease. Aust N Z J Obstet Gynaecol. 1995;35:357-362.
95. Cowchock PS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: A collaborative randomized trial comparing prednisone with low-dose heparin. Am J Obstet Gynecol. 1992;166: 1318-1323.
96. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996;174:1584-1589.
97. Rai R, Cohen H, Regan L. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997;314:253-257.
98. Nobunaga T, Tokugawa Y, Hashimoto K, et al. Plasma nitric oxide levels in pregnant patients with preeclampsia and essential hypertension. Gynecol Obstet Invest. 1996;41:189-193.
99. Buhimschi IA, Saade GR, Chwalisz K, Garfield RE. The nitric oxide pathway in preeclampsia: Pathophysiological implications. Hum Reprod Update. 1998;4:25-42.
100. Lopez-Jaramillo P. Prevention of preeclampsia with calcium supplementation and its relation with the L-arginine:nitric oxide pathway. Braz J Med Biol Res. 1996;29:731-741.